The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Sanofi BelgiumEU/1/13/869/001

Main Information

Trade NameLemtrada
Active SubstancesAlemtuzumab
Dosage FormConcentrate for solution for infusion
Licence HolderSanofi Belgium
Licence NumberEU/1/13/869/001

Group Information

ATC CodeL04AA Selective immunosuppressants
L04AA34 Selective immunosuppressants


License statusAuthorised
Licence Issued
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal products on “restricted” medical prescription, reserved for use in certain specialised areas (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back